Crizotinib was the first ALK inhibitor to be approved for the treatment of ALK fusion-positive NSCLC, followed by ceritinib, alectinib, brigatinib, and lorlatinib.3,5 These ALK inhibitors have revolutionized the treatment of patients with ALK fusion-positive NSCLC, and are approved as front-line treatment options for these patients.3,6-15 Recent data have also demonstrated a clinical benefit for ALK inhibition in patients with ALK fusion-positive NSCLC in the adjuvant setting, resulting in the approval of alectinib in this setting.10,16. The gene discussed is ALK; the disease is non-small cell lung carcinoma.